When you consider ENBREL, think of safety experience demonstrated over 10 years
ENBREL has been evaluated in clinical studies over the past 18 years* and has more than 10 years of continuous safety data in RA clinical trials.
Discover more about the history of ENBREL "NOW"
*Initial clinical research in rheumatoid arthritis (RA) patients began in 1993. ENBREL was FDA-approved to treat moderate to severe rheumatoid arthritis in 1998.
†First tumor necrosis factor inhibitor approved in the US for moderate to severe RA, moderately to severely active polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis.
‡DMARD = disease-modifying antirheumatic drug